読み込み中
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
前日終値
$6.865
−$0.175 · -2.49%
時間外
$6.86
−$0.005 · -0.07%
10月12日 19:24 ET
日中の時刻はETです。市場データは遅延する場合があります。
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
日中レンジ
現在 $6.865
52週レンジ
現在 $6.865
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
49
適正価値
センチメント
42
まちまち
リスク
86
極めて高いリスク
モメンタム
35
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
日中レンジ
現在 $6.865
52週レンジ
現在 $6.865
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1.17億 USD | 1.06億 USD | 1.13億 USD | 1.02億 USD | 733.8万 USD |
| 売上原価 | 541.6万 USD | 388.4万 USD | 463.6万 USD | 479.3万 USD | 767万 USD |
| 粗利益 | 1.11億 USD | 1.02億 USD | 1.09億 USD | 9749.7万 USD | −33.2万 USD |
| 研究開発 | 1369.8万 USD | 1202.4万 USD | 1378万 USD | 1668.6万 USD | 6457.4万 USD |
| 販売・一般管理 | 8598.3万 USD | 7362万 USD | 7582.1万 USD | 7160.8万 USD | 1882万 USD |
| 営業費用 | 9968.1万 USD | 8571万 USD | 1.76億 USD | 8829.4万 USD | 8339.4万 USD |
| 受取利息 | 174.7万 USD | 154.7万 USD | 104.4万 USD | 72.6万 USD | 3.9万 USD |
| 減価償却費と償却費 | 248.1万 USD | 158.8万 USD | 111.4万 USD | 112.9万 USD | 29万 USD |
| 営業利益 | 1149.1万 USD | 1622.9万 USD | −6723万 USD | 920.3万 USD | −8372.6万 USD |
| 純利益 | 502.7万 USD | 1208.5万 USD | −9293.3万 USD | 230.2万 USD | −8793.3万 USD |
会社概要が更新されました 2026年10月13日.
直近の発表実績
直近の発表実績
| 種別 | 配当落ち日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
配当 | 2023年1月13日 | $0.24Quarterly | 2023年1月5日 | — |
配当 | 2022年9月21日 | $1.43Quarterly | 2022年9月6日 | — |
配当 | 2015年8月20日 | $0.569Quarterly | — | — |
配当落ち 2023年1月13日
$0.24
Quarterly
2023年1月5日基準
配当落ち 2022年9月21日
$1.43
Quarterly
2022年9月6日基準
配当落ち 2015年8月20日
$0.569
Quarterly
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
